Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7505036 | 0.85 | L3MBTL1 (0.39) | ALDH1A1GLAL3MBTL1HPGDMEN1 | |
| SCHEMBL10460022 | 0.84 | ALDH1A1 (0.55) | ALDH1A1GLATDP1MGLLTP53 | |
| SCHEMBL4371199 | 0.83 | ALDH1A1 (0.54) | ALDH1A1GLATDP1MGLLTSHR | |
| SCHEMBL1140449 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GLATDP1TP53CYP3A4 | |
| SCHEMBL27698019 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GLATDP1TP53CYP3A4 | |
| SCHEMBL4276592 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GLATDP1TP53CYP3A4 | |
| SCHEMBL29618932 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GLATDP1TP53CYP3A4 | |
| SCHEMBL1745602 | 0.80 | ALDH1A1 (0.66) | ALDH1A1GLATDP1MGLLTP53 | |
| SCHEMBL11162254 | 0.80 | ALDH1A1 (0.61) | ALDH1A1GLATDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL6221087 | 0.79 | THRA (0.61) | ALDH1A1GLATDP1MGLLTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7528156-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7345063-B2 | Amides, preparation and therapeutic use as modulators of CCR-receptor activity | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1263760-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002076457-A1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| EP-0050885-B1 | PROCESS FOR PREPARING 1-AMINO-3-ARYLOXY-2-PROPANOLS AND 1-AMINO-2-ARYL-2-ETHANOLS | BLASCHIM S.p.A. (IT) | 1984-07-18 | — | — | EP | disclosed |
| EP-0050885-A2 | Process for preparing 1-amino-3-aryloxy-2-propanols and 1-amino-2-aryl-2-ethanols | BLASCHIM S.p.A. (IT) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | ALDH1A1 3937/4885GLA 4423/4885TDP1 582/4885 |
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | ALDH1A1 1779/4885GLA 2979/4885TDP1 3305/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | ALDH1A1 949/4885GLA 1596/4885TDP1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.